56 results
424B3
OCUP
Ocuphire Pharma Inc
16 Feb 24
Prospectus supplement
4:31pm
insurance policies are expensive and protect only from some business risk, which leaves us exposed to significant uninsured liabilities;
environmental
424B5
76p iz870vk
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
bw6bn
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
424B5
36jfg wn2
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-10.1
bce39d03a6nygjjjne8i
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
wjktc 9a50k584yba0q6
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B5
d559iogy2qxjubbt65
11 Mar 21
Prospectus supplement for primary offering
9:19am
8-K
EX-1.1
7a95i3j481un0i57
11 Mar 21
Entry into a Material Definitive Agreement
8:34am
424B4
n3uxuy 4w4
17 Feb 21
Prospectus supplement with pricing info
7:14am
D
11qn5la1e qnuxhjl
20 Nov 20
$21.15M in equity / options / securities to be acquired, sold $21.15M, 18 investors
3:21pm
8-K
EX-14.1
i5vt8g113 2n5syq5why
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
424B3
re36mfj2h4a
2 Oct 20
Prospectus supplement
9:25am